

Bayer Commitment



Narrative:

Bayer will build on its commitment to the ICPD Programme of Action.

Bayer's long-term commitment to family planning in accordance with the ICPD Programme of Action and 2030 SDGs will be reinforced in support of the FP2030 partnership. At the 25th anniversary commemoration of the ICPD, Bayer made a commitment to help provide 100 million women in low- and middle-income countries with access to modern contraception by 2030. This ambitious goal can be reached not only through intensifying Bayer's role as a strategic supplier to family planning programs but via capacity building partnerships.

The company has been supporting family-planning programs by supplying a broad range of hormonal contraception methods for many years, encompassing both short- and long-acting products. Increasing demand in low- and low-middle-income countries has been seen particularly regarding long-acting, reversible contraceptives (LARCs), including implants.

- Bayer commits to ensuring sufficient supply for LARCs in LMICs through building a new production facility in Costa Rica with an investment of 160m USD. Starting in 2024, Bayer's long-acting implant and hormonal IUD will be manufactured at two sites, both in Finland and Costa Rica, increasing supply security for LMICs. Both sites will have carbon neutral operations.
- At the same time, Bayer is reinforcing measures to improve traceability of products and supply coordination within the FP ecosystem. Bayer has joined "GlobalFPVan" and will increase the regulatory footprint for its products, including the hormonal IUD, which has been added to the product catalogues of UNFPA and USAID.
- Bayer is expanding its social business model for Family Planning by reinvesting all profits from supranational sales in capacity building programs and partnerships
- These partnerships include Bayer's contribution to "The Challenge Initiative", hosted at the Bill & Melinda Gates Institute at Johns Hopkins University. Beyond its initial grant, Bayer continues to engage in the further support and development of this highly effective and sustainable program which is advancing the institutionalization of family planning in low-resource urban settings. Bayer's commitment to the program for 2020 to 2025 has a value of 42.5m USD.
- As another example for partnerships in support of its FP2030 commitment, Bayer and the German Red Cross (GRC) have joined forces to co-create a Family Planning Module for the GRC to deliver Family Planning in its humanitarian response to emergencies and protracted crisis.
- Bayer embraces innovation with its Equalizer Innovation Fund membership
- Bayer has entered into a grant agreement with the Bill & Melinda Gates Foundation. As part of the agreement, Bayer and the Bill & Melinda Gates Foundation have committed more than US\$ 12 million each to co-fund pre-clinical research activities with the goal of providing women globally with an option for non-hormonal contraception. In addition to research co-funding over a four-year period, Bayer will leverage its experience in women's healthcare as well as research and development expertise in order to identify a pre-clinical development candidate. Bayer has also committed to make such a product available in low- and lower-middle-income countries at an affordable price once it would have been approved by health authorities

- Bayer expands its adolescent and youth-centric health program under the umbrella of the World Contraception Day (WCD) initiative and the related Your Life campaign to support increased levels of awareness and knowledge about sexual and reproductive health amongst adolescents and youth worldwide through the provision of medically accurate and unbiased sexuality education via national, regional and global programs.

Outcomes:

100 million women in low- and middle-income countries reached with access to modern contraceptives.